HealthEquity, Inc
HQY
$81.18
-2.80%
HealthEquity, Inc. is a leading provider of technology-enabled services that empower consumers to make healthcare saving and spending decisions, operating within the Medical - Healthcare Information Services industry. The company is a dominant player in the Health Savings Account (HSA) and consumer-directed benefits administration space, managing a critical financial nexus for employers and employees. The current investor narrative is focused on the company's recovery and growth trajectory following a period of operational challenges, with recent financials showing a significant rebound in profitability and revenue growth, which is driving a reassessment of its earnings power and market position.…
HQY
HealthEquity, Inc
$81.18
Investment Opinion: Should I buy HQY Today?
Rating: Hold. The core thesis is that HQY presents a compelling fundamental recovery story trapped within a broken technical and sentiment picture, creating a high-risk/high-reward scenario that currently favors caution. While analyst sentiment is generally positive, the stock's action tells a different story.
The fundamental improvements are significant: a forward P/E of 15.44x is attractive for a company with 7.3% revenue growth and a net margin that has recovered to 16.4%. The $439M in TTM free cash flow and strong balance sheet (current ratio 3.27) provide a margin of safety. However, these positives are counterbalanced by the stock trading just 21.8% above its 52-week low, showing a -34.53% relative strength deficit, and carrying a high short ratio of 3.52, indicating deep-seated skepticism.
The two biggest risks are 1) the sustainability of the Q4 gross margin and profit surge, and 2) a failure of the price to find a bottom, leading to a breakdown below $72.76. This Hold would upgrade to a Buy on a confirmed breakout above the $90-$95 resistance zone on heavy volume, signaling institutional accumulation and a shift in momentum. It would downgrade to a Sell on a confirmed break below the $72.76 support or if next-quarter earnings show the margin expansion was a one-time event. Relative to its own history and growth trajectory, the stock appears fairly valued to slightly undervalued on a forward basis, but the technical and sentiment overhang justifies a neutral stance.
Sign up to view all
HQY 12-Month Price Forecast
HQY is a classic 'show me' story. The fundamental repair job is impressive on paper, with soaring profits and cash flow, but the market clearly doubts its durability, as evidenced by the stock's persistent downtrend and proximity to 52-week lows. The base case of range-bound consolidation is most likely, as the company needs to string together several quarters of stable, high-quality earnings to rebuild credibility. The stance is neutral due to the high degree of binary risk around the next earnings report; a confirmation of the new profit paradigm would be bullish, while a reversion would be bearish. Confidence is medium because while the data points are clear, their interpretation and sustainability are fiercely debated by the market itself.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on HealthEquity, Inc's 12-month outlook, with a consensus price target around $105.53 and implied upside of +30.0% versus the current price.
Average Target
$105.53
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$65 - $106
Analyst target range
Insufficient analyst coverage is available, with only two analysts providing estimates according to the provided data. This limited coverage typically indicates the stock is a mid-cap name with constrained institutional research interest, which can lead to higher volatility and less efficient price discovery. The available data shows estimated EPS for the next period averaging $6.20, with a range from $6.10 to $6.32, implying strong expected profitability. The institutional ratings data shows a pattern of reiterated bullish stances from several firms (Deutsche Bank, JP Morgan, Barrington Research, RBC Capital, Barclays, BTIG, Keybanc) in early 2026, with one notable downgrade to Sell from Goldman Sachs in January 2026. The prevalence of Overweight, Outperform, and Buy ratings suggests a generally positive institutional sentiment, though the low analyst count and the presence of a Sell rating highlight underlying uncertainty and debate regarding the company's outlook.
Bulls vs Bears: HQY Investment Factors
The evidence presents a stark conflict between improving fundamentals and persistently weak price action. The bull case is grounded in a concrete, dramatic recovery in profitability, strong cash flow, and a reasonable forward valuation. The bear case is equally concrete, pointing to a stock in a severe technical downtrend, trading near 52-week lows with significant short interest, and facing questions about the sustainability of its margin surge. Currently, the bearish technical momentum and skepticism reflected in the price outweigh the bullish fundamental improvements, as the market appears to doubt the durability of the recovery. The single most important tension is the sustainability of the Q4 2026 profitability surge—specifically, whether the anomalous 92.4% gross margin and the associated earnings power are repeatable or a one-time event. The resolution of this question will determine if the stock re-rates higher on its forward P/E or continues to be discounted.
Bullish
- Dramatic Profitability Recovery: Net income surged to $49.7M in Q4 2026 from $26.4M a year ago, a near doubling. This is supported by a gross margin expansion to 92.4% in the latest quarter, though this specific figure appears anomalous, the operating margin of 24.6% confirms a robust underlying profit recovery.
- Strong Free Cash Flow Generation: The company generated $439.1M in trailing-twelve-month free cash flow, providing significant internal funding for growth and shareholder returns. This strong cash generation underpins a healthy balance sheet with a current ratio of 3.27 and a manageable debt-to-equity of 0.48.
- Attractive Forward Valuation: The forward P/E ratio of 15.44x is less than half the trailing P/E of 34.29x, reflecting market expectations for significant earnings growth. This forward multiple is reasonable for a company showing a 7.3% YoY revenue growth and a dramatic profit rebound.
- Positive Institutional Sentiment: Despite limited coverage, analyst sentiment is predominantly bullish, with multiple firms (Deutsche Bank, JP Morgan, RBC, etc.) reiterating Overweight or Buy ratings in early 2026. The average estimated EPS for the next period is a strong $6.20.
Bearish
- Severe Technical Downtrend & Weakness: The stock is down 3.94% over the past year and trades at just 21.8% of its 52-week range ($72.76-$116.65), near its low. It has shown persistent negative relative strength of -34.53% vs. the S&P 500 over the past year, indicating deep-seated selling pressure.
- Anomalous Gross Margin Raises Questions: The Q4 2026 gross margin of 92.4% is a massive jump from 60.7% a year ago, driven by a sharp, unexplained drop in cost of revenue. This volatility casts doubt on the sustainability of the reported margin improvement and suggests potential one-time benefits or accounting changes.
- Limited Analyst Coverage & High Short Interest: Only two analysts provide estimates, indicating limited institutional research interest which can lead to inefficient price discovery and higher volatility. A short ratio of 3.52 suggests a significant portion of the market is betting against the stock's near-term prospects.
- Valuation Compression from High Levels: The trailing P/E of 34.29x remains elevated compared to sector averages, and the stock's own P/E has compressed from over 90x earlier in 2025. This indicates the market is still discounting the sustainability of the earnings recovery, fearing a reversion.
HQY Technical Analysis
The prevailing price trend for HealthEquity is a sustained downtrend, with the stock down 3.94% over the past year and trading significantly closer to its 52-week low of $72.76 than its high of $116.65. At its current price of $82.45, it is positioned at just 21.8% of its 52-week range, indicating deep value territory but also reflecting persistent negative momentum and a lack of bullish catalysts. Recent momentum shows continued weakness, with the stock down 2.43% over the past month and 1.97% over the past three months, suggesting the longer-term downtrend remains intact despite some intra-quarter volatility. The stock's beta of 0.262 indicates it has been significantly less volatile than the broader market, which has rallied strongly (SPY up 30.59% over the past year), highlighting a severe and persistent negative relative strength of -34.53% over the same period. Key technical support is firmly established at the 52-week low of $72.76, while resistance lies at the 52-week high of $116.65. A breakdown below $72.76 would signal a new leg down and potential fundamental deterioration, while a sustained move above the recent trading range would require a significant positive catalyst. The stock's low beta suggests it has been a defensive laggard, but its deep drawdown of -35.25% indicates it has not provided downside protection, instead suffering from company-specific issues.
Beta
0.26
0.26x market volatility
Max Drawdown
-35.3%
Largest decline past year
52-Week Range
$73-$117
Price range past year
Annual Return
-3.8%
Cumulative gain past year
| Period | HQY Return | S&P 500 |
|---|---|---|
| 1m | -1.6% | +12.2% |
| 3m | -2.0% | +2.3% |
| 6m | -12.7% | +4.7% |
| 1y | -3.8% | +29.2% |
| ytd | -10.9% | +4.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HQY Fundamental Analysis
Revenue growth has shown a positive trajectory, with the most recent quarterly revenue of $334.59 million representing a 7.3% year-over-year increase. This growth has been consistent, with sequential quarterly revenues of $322.16M, $325.84M, and $330.84M in the preceding periods, indicating stable, mid-single-digit expansion. The revenue segment data, though limited, shows the largest contribution from 'Financial Service, Other' at $161.40 million, followed by 'Service' at $127.08 million, suggesting diversified income streams. Profitability has dramatically improved, with the company reporting net income of $49.74 million in the latest quarter, a stark contrast to the $26.37 million reported in the year-ago quarter. Gross margin expanded significantly to 92.4% from 60.7% a year ago, though this appears to be an anomaly driven by a sharp drop in cost of revenue; the operating margin of 24.55% provides a more normalized view of core profitability. The balance sheet and cash flow position are strong, with a current ratio of 3.27 indicating ample liquidity and a manageable debt-to-equity ratio of 0.48. The company generated robust free cash flow of $439.07 million over the trailing twelve months, providing significant internal funding capacity for growth and shareholder returns, as evidenced by substantial stock repurchase activity in recent quarters.
Quarterly Revenue
$334586000.0B
2026-01
Revenue YoY Growth
+0.07%
YoY Comparison
Gross Margin
+0.92%
Latest Quarter
Free Cash Flow
$439068000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HQY Overvalued?
Given the company's positive net income of $49.74 million in the latest quarter, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 34.29x, while the forward PE is significantly lower at 15.44x, indicating the market expects a substantial near-term earnings acceleration, which aligns with the recent quarterly profit surge. Compared to sector averages, HealthEquity's trailing PE of 34.29x is elevated, but its forward multiple of 15.44x suggests the premium is based on anticipated growth. The Price-to-Sales ratio of 5.62x and EV/Sales of 5.52x provide additional context for a business transitioning to higher profitability. Historically, the stock's own valuation has compressed from much higher levels; for instance, its PE ratio was 90.77x as of January 2025. The current trailing PE of 34.29x is near the middle of its recent historical range, having come down from extreme heights as earnings have recovered, suggesting the market has partially priced in the profitability improvement but may still be discounting sustainability concerns.
PE
34.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -6166x~326x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on the volatility and sustainability of the company's newfound profitability. The gross margin spike to 92.4% in Q4 2026, from a more normalized ~60-70% range in prior quarters, is a major red flag; if this proves temporary, earnings could sharply disappoint. Revenue growth, while stable, is only in the mid-single digits (7.3% YoY), which may be insufficient to justify a premium valuation if growth decelerates. The company's valuation remains sensitive to earnings delivery, with a forward P/E of 15.44x still embedding significant growth expectations that must be met.
Market & Competitive Risks are pronounced given the stock's severe underperformance. HQY's beta of 0.26 suggests it should be a low-volatility defensive stock, yet its -35.25% max drawdown and -34.53% relative strength vs. the S&P 500 over the past year show it has suffered company-specific de-rating. Trading at a trailing P/E of 34.29x, it carries valuation compression risk if the market continues to question its growth story or if sector multiples contract. Competitive pressures in the HSA administration space and potential regulatory changes to consumer-directed health plans pose ongoing external threats.
Worst-Case Scenario involves the Q4 profitability surge being definitively identified as non-recurring, leading to a significant earnings miss and guidance cut in the next quarterly report. This could trigger a cascade of analyst downgrades, intensify short-selling pressure (short ratio 3.52), and force a re-test and break below the key 52-week low support of $72.76. In this adverse scenario, the stock could realistically fall to the $65-$70 range, representing a downside of -15% to -21% from the current price of $82.45, as the market prices in a reversion to lower, pre-recovery earnings multiples.
FAQ
The primary risk is Earnings Sustainability: the dramatic Q4 gross margin jump to 92.4% may not be repeatable, risking a sharp earnings decline. Technical Risk: the stock is in a powerful downtrend, down 3.94% over the past year with a -34.53% relative strength, and a break below $72.76 support could trigger another leg down. Sentiment & Liquidity Risk: with only two analyst estimates and a short ratio of 3.52, the stock is prone to sharp moves on limited news. Competitive/Market Risk: slower HSA market growth or increased competition could pressure the steady 7.3% revenue growth.
The 12-month forecast presents three scenarios. The Base Case (50% probability) sees the stock trading between $85 and $95 as it consolidates, requiring proof of stable profitability. The Bull Case (30% probability) targets $105 to $116, requiring confirmation of the new high-margin regime and accelerated growth. The Bear Case (20% probability) warns of a drop to $65-$73 if Q4 profits were a mirage and support breaks. The base case is most likely, implying modest upside from current levels but contingent on the company delivering consistent quarterly results to rebuild investor trust.
HQY's valuation is bifurcated. On a trailing basis, with a P/E of 34.29x, it appears expensive relative to its mid-single-digit revenue growth. However, the forward P/E of 15.44x, based on an estimated EPS of $6.20, suggests the market is pricing in significant near-term earnings growth and views the stock as fairly valued to slightly undervalued if that growth materializes. The key is the gross margin; if it stabilizes at a new, higher plateau, the current forward multiple could be cheap. If it reverts, the stock is overvalued. The market is currently assigning a high uncertainty discount, as seen in the stock's depressed price.
HQY is a high-risk, potentially high-reward investment that is not a straightforward 'good buy' for all investors. For a value-oriented investor seeking a turnaround story with strong cash flow and a reasonable forward P/E of 15.44x, it may warrant a small, speculative position. However, the severe technical downtrend, trading near 52-week lows, and high short interest of 3.52 make it a dangerous buy for the risk-averse. It could be a good buy for those who believe the profitability recovery is real and are willing to wait through potential further volatility, but it requires a strong stomach and a long-term horizon.
HQY is unsuitable for short-term trading due to its low beta (0.26) but high idiosyncratic volatility and broken momentum; it lacks the predictable catalysts for a quick trade. It is a long-term, speculative investment for investors with a minimum 2-3 year horizon. This timeframe is necessary to allow the company to demonstrate the sustainability of its operational turnaround across multiple economic and business cycles, for the technical chart to potentially base and repair, and for the valuation re-rating to occur if the thesis proves correct. The lack of a dividend further supports a growth-oriented, long-term holding strategy.
